-
2023-504331-41-00
5
2024-08-02
Respiratory tract diseases - Wheezing, Asthma
-
2023-507204-31-00
5
2024-07-26
Hidradenitis Suppurativa
-
2023-509947-29-00
4
2024-07-18
Anemia in patients with very low, low or intermediate risk myelodyspla
-
2023-503594-38-00
1
2024-07-15
Select B-Cell malignancies.
-
2023-505061-82-01
5
2024-06-17
Alopecia Areata
-
2023-505722-33-00
4
2024-04-15
cholangiocarcinoma or gallbladder carcinoma
-
2024-517959-12-00
9
2024-04-11
Relapsed/refractory B cell precursor acute lymphoblastic leukemia
-
2023-507448-36-00
5
2024-02-16
Non-small Cell Lung Cancer
-
2024-514458-61-01
4
2024-02-05
HER2+ early breast cancer
-
2023-503240-13-00
5
2024-01-30
Hypoglycemia associated with congenital hyperinsulinism
-
2022-502110-85-00
5
2024-01-18
Peanut allergy
-
2023-506139-13-00
5
2024-01-04
Treatment naïve patients with MF
-
2022-501406-36-00
3
2023-12-14
Myeloid disease
-
2023-505976-31-00
5
2023-11-24
Systemic Sclerosis (SSc) presenting with Limited or Diffuse Cutaneous
-
2023-503265-27-00
5
2023-11-23
Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Co
-
2023-505023-31-00
5
2023-11-17
Renal cell carcinoma
-
2023-506821-12-00
5
2023-10-12
Estrogen Receptor (ER)-Positive, HER2-Negative, Locally Advanced or Me
-
2022-500430-29-00
5
2023-10-11
Myelodysplastic Syndrome (MDS)
-
2022-502632-39-00
1
2023-10-11
Systemic Lupus Erythematosus (SLE)
-
2023-504028-24-00
5
2023-09-22
Large B-Cell Lymphoma
-
2024-515224-37-00
4
2023-08-29
Patients with MSI-high or MMR-deficient stage III colorectal cancer wh
-
2024-515047-31-00
5
2023-08-28
Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) at stage
-
2022-501024-20-00
5
2023-07-25
ER+/HER2- Early Breast Cancer
-
2024-516536-10-00
4
2023-05-25
Locally advanced head and neck squamous cell carcinoma